# Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma

> **NCT06620926** · — · COMPLETED · sponsor: **asmaa salama ibrahim** · enrollment: 811 (actual)

## Conditions studied

- Astrocytoma
- Astrocytic Tumors
- Astrocytoma of Brain

## Interventions

- **OTHER:** IDH mutant-type
- **OTHER:** IDH wild-type

## Key facts

- **NCT ID:** NCT06620926
- **Lead sponsor:** asmaa salama ibrahim
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 811 (ACTUAL)
- **Last updated:** 2024-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06620926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06620926, "Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06620926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*